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ABSTRACT
Background. We retrospectively reviewed the long-term
outcome and late side effects of endometrial cancer (EC)
patients treated with different techniques of postoperative
radiotherapy (PORT).
Methods. Between 1999 and 2012, 237 patients with EC
were treated with PORT. Two-dimensional external beam
radiotherapy (2D-EBRT) was used in 69 patients (30 %),
three-dimensional EBRT (3D-EBRT) in 51 (21 %), and
intensity-modulated RT (IMRT) with helical Tomotherapy
in 47 (20 %). All patients received a vaginal brachytherapy
(VB) boost. Seventy patients (29 %) received VB alone.
Results. After a median of 68 months (range, 6–154) of
follow-up, overall survival was 75 % [95 % confidence
interval (CI), 69–81], disease-free survival was 72 % (95%
CI, 66–78), cancer-specific survival was 85 % (95 % CI,
80–89), and locoregional control was 86 % (95 % CI,
81–91). The 5-year estimates of grade 3 or more toxicity
and second cancer rates were 0 and 7 % (95 % CI, 1–13)
for VB alone, 6 % (95 % CI, 1–11) and 0 % for
IMRT ? VB, 9 % (95 % CI, 1–17) and 5 % (95 % CI,
1–9) for 3D-EBRT ? VB, and 22 % (95 % CI, 12–32) and
12 % (95 % CI, 4–20) for 2D-EBRT ? VB (P = 0.002
and P = 0.01), respectively.
Conclusions. Pelvic EBRT should be tailored to patients
with high-risk EC because the severe late toxicity observed
might outweigh the benefits. When EBRT is prescribed for
EC, IMRT should be considered, because it was associated
with a significant reduction of severe late side effects.
Endometrial cancer (EC) is the most common gyneco-
logic malignancy in developed countries.1,2 At the time of
diagnosis, most patients present with early-stage disease,
and low-risk patients have a risk of locoregional recurrence
(LRR) of 5–10 %. However, high- to intermediate-risk
patients harbor a combination of high-grade, deep myo-
metrial invasion and/or lymphovascular space invasion
(LVSI), with a risk of LRR of up to 27 %.3 Randomized
studies have shown that postoperative radiotherapy
(PORT) decreases the LRR rate without affecting overall
survival (OS). However, two-thirds of the patients in those
trials had low-risk disease and a substantial risk of dying as
a result of competing hazards.3–8 The long-term outcome
of these trials also confirmed the morbidity risks of adju-
vant PORT using mainly two-dimensional (2D) external
beam radiotherapy (EBRT) techniques.9 The postoperative
radiotherapy in EC (PORTEC-2) randomized trial showed
that the toxicity of PORT using three-dimensional (3D)-
EBRT techniques outweighs the benefits and that vaginal
brachytherapy (VB) alone can be enough to avoid local
recurrences in the subgroup of patients with high- to
intermediate-risk factors (grade 1–2 tumors, [50 % myo-
metrial invasion, endometrioid type, age[60 years, and no
LVSI).10 Pelvic radiotherapy (RT) has changed dramati-
cally over the last few decades with the introduction of
intensity-modulated RT (IMRT). The question that remains
open is whether IMRT will lead to a reduced rate of severe
side effects. Studies have found evidence of an increased
risk of secondary neoplasms after PORT, and some
investigators have recently postulated that IMRT can
potentially increase the risk of second cancers.9,11,12 We
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aimed in this study to assess a population-based cohort who
received adjuvant PORT over a 12-year period with dif-
ferent technique of RT. In our series, IMRT was delivered
with helical Tomotherapy (Accuray, Madison, WI). To-
motherapy is a new generation 6-MV photon accelerator
that allows helical delivery of highly conformal and
homogeneous doses associated with daily image-guided
RT. We assessed the severe late toxicity (grade 3 or more)
and the incidence of second cancers.
METHODS
Study Population
After approval by the local ethics committee, we retro-
spectively reviewed the charts of 237 eligible patients from
a total of 245 EC patients who received adjuvant PORT
between 1999 and 2012 at the Lausanne University Hos-
pital. Inclusion criteria were a pathologic diagnosis of EC,
stage I–IVA according to the International Federation of
Gynecology and Obstetrics (FIGO) 1988 definition, and a
minimum of 6 months of follow-up.13 One patient was
excluded from the analysis because of disseminated dis-
ease, and 7 patients were excluded for incomplete follow-
up. Data were obtained from the electronic and written
medical records and included age at diagnosis, date of
diagnosis, date of surgery, type of surgical procedure,
number of pathologically examined lymph nodes, surgical
margins, histology, grade, depth of myometrial invasion,
stage, LVSI, type and dose of PORT, date and location of
recurrence, date of last follow-up, date of death, incidence
and types of second cancers, and late side effects (grade 3
or more) based on common terminology criteria for
adverse events version 4.0, which were confirmed from
follow-up records and surgical and/or procedural inter-
ventions. Sites of failure were grouped into isolated vaginal
recurrence, LRR (pelvic and/or paraaortic), and distant
metastases (extraabdominal sites and positive peritoneal
cytology).
Statistical Considerations
Proportions were compared by using the Chi square test
for values of 5 or higher and with Fisher’s exact test for
values of less than 5. Survival curves were estimated by
using the Kaplan–Meier method. Time to any event was
measured from the day RT started. Death certificates
confirmed date of deaths. If clinical or pathologic evidence
of active, recurrent disease was present, deaths were
attributed to EC. The events were death (all causes) for OS,
EC-related mortality for cancer-specific survival (CSS),
and death (all causes) or relapse for disease-free survival
(DFS). For the locoregional control (LRC) rate, the event
consisted of local or regional relapse. Confidence intervals
(CI) were calculated from standard errors. In univariate
analyses, differences between groups were assessed by
using the log-rank test. All obtained significant P values
were corrected for multiple comparisons with the Bonfer-
roni correction method in which the P values are multiplied
by the number of comparisons. In multivariate analyses, we
screened for prognostic factors with a P value of less than
0.05 in univariate analyses by using the Cox regression
analysis to define the independent contribution of each
prognostic factor. A P value of\0.05 was considered to be
statistically significant. All data were examined using JMP
version 9.0.1 (SAS Institute Inc., Cary, NC).
RESULTS
Patient Characteristics
A total of 237 patients with EC were identified with
complete follow-up. Patients’ surgical, pathologic, and
treatment characteristics are detailed in Table 1. The
median age was 69 years (range, 37–90 years).
Surgery
All patients underwent total abdominal hysterectomy
and bilateral salpingo-oophorectomy (TAH-BSO) includ-
ing abdominal washing, with (n = 126) or without
(n = 111) lymphadenectomy.
Radiotherapy
RT started 6–8 weeks after surgery and was delivered
by using a two-dimensional four-field technique
(2D-EBRT) in 69 patients (30 %), four-field conformal RT
(3D-EBRT) in 51 (21 %), and Tomotherapy in 47 (20 %).
All of the patients treated in the Tomotherapy group had
daily image-guided RT using helical megavoltage-based
computed tomography. All patients treated with different
techniques of EBRT also received a VB boost. Seventy
patients (29 %) were treated with postoperative VB alone.
Patients treated with 2D-EBRT had the radiation portals
determined using a kilovoltage simulator. From the intro-
duction of 3D-EBRT, target volumes and organs at risk
were contoured on a computed tomography image, and
personalized shielding was applied by using the multileaf
collimator. For both 2D-EBRT and 3D-EBRT, the radia-
tion fields extended from the anterior aspect of the pubic
symphysis to the L5–S1 interspace and laterally posteriorly
up to the middle sacrum. With the introduction of helical
Tomotherapy, the radiation volumes were based on the
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radiation therapy oncology group consensus guidelines,
including the irradiation of common iliac nodes.14 The
median EBRT dose was 45 Gy (range, 41.4–50.4 Gy) in
fractions of 1.8 Gy. VB was administered to the upper
3 cm of the vagina by using a high-dose rate technique
delivered via vaginal cylinders; the dose was prescribed to
the vaginal mucosa (0.5 cm from the cylinder surface). The
median number of VB fractions was 3 (range, 2–6), and the
median VB dose was 5 Gy per fraction (range, 3–7.5 Gy).
The most frequent VB regimen was 10 Gy in 2 fractions
for those previously receiving EBRT (VB boost) and
20 Gy in 4 fractions for those only receiving VB.
Disease Outcome
In a median follow-up of 68 months (range,
6–154 months), the 5-year OS was 75 % (95 % CI, 69–81),
DFS was 72 % (95 % CI, 66–78), CSS was 85 % (95 %
CI, 80–89), and LRC was 86 % (95 % CI, 81–91). By the
end of follow-up, 161 of 237 (68 %) patients were alive
without disease, and 12 of 237 were alive with recurrent
disease. Thirty-three of 237 (14 %) patients died of EC,
and 31 of 237 (13 %) died of intercurrent diseases
(24 cardiovascular, 6 s tumors, and 1 treatment-related
toxicity). A total of 47 patients (20 %) experienced a
recurrence. In univariate analyses, statistically significant
factors unfavorably influencing OS and DFS were patient
age ([69 years), presence of LVSI, advanced stage, pap-
illary-serous or clear-cell histology, grade 3 tumors,
absence of lymphadenectomy, presence of positive lymph
nodes, and positive abdominal washing. For CSS and LRC,
the previously mentioned parameters applied, except for
age (Table 2). After multivariate analyses, the remaining
independent prognostic factors unfavorably influencing
OS and DFS were age ([69 years), advanced stage, posi-
tive LVSI, absence of lymphadenectomy, and grade 3
histology. For CSS and LRC, the previously mentioned
variables applied except for age (Table 3).
The 5-year LRC rate was 89 % (95 % CI, 80–96) for
patients treated with VB alone versus 85 % (95 % CI,
79–91) for those treated with EBRT ? VB (P = 0.5).
Among those treated with VB alone, there was an increased
proportion of patients with endometrioid-type histology
[endometrioid type (n = 62) versus serous type or clear
cell (n = 8); P = 0.0026], grade 1–2 [grade 1–2 (n = 67)
versus grade 3 (n = 3), P \ 0.0001], earlier-stage tumors
[Ia, b, and IIa (n = 23), Ic (n = 42), and IIb (n = 5);
P \ 0.0001], and absence of LVSI [LVSI absent (n = 64),
LVSI present (n = 6); P \ 0.0001]. When comparing
patients (n = 60) who fit the PORTEC-2 inclusion criteria,
i.e., stage I tumors, patients [60 years old (Ic and grade 1
or 2), or Ib (grade 3) or stage IIa tumors at any age
excluding grade 3 or [50 % myometrial invasion, with
those without the PORTEC-2 criteria (n = 177), the 5-year
LRC was 96 % (95 % CI, 91–100) versus 83 % (95 % CI,
77–89; P = 0.02), respectively.10
Toxicity
By the end of follow-up, 24 patients (9.7 %) developed
severe late toxicity (grade 3 or more). Two patients
developed urethral stenosis requiring surgery, resulting in
permanent urinary incontinence. Three patients developed
synchronous urethral stenosis and rectovaginal fistulas.
Sixteen patients had intestinal toxicity (bowel stenosis and/
or rectovaginal fistulas). One patient died because of small-
TABLE 1 Patients’ surgical, pathologic, and treatment characteris-
tics (n = 237)
Characteristic n %
1988 FIGO stage
Ia 5 2
Ib 54 22.7
Ic 75 31.6
IIa 16 6.7
IIb 46 19.4
IIIa 6 2.5
IIIb 2 0.8
IIIc 30 12.6
IVa 1 0.4
LVSI
Positive 77 32.5
Negative 160 67.5
Grade
1–2 169 71.3
3 68 28.6
Histology
Clear cell/serous papillary 56 23.6
Endometrial type 181 76.3
Pelvic lymphadenectomy
Performed 126 53
Not performed 111 47
Paraaortic lymphadenectomy
Performed 35 14.7
Not performed 202 85.2
Radiotherapy technique
VB 70 29.5
2D-EBRT ? VB 69 29
3D-EBRT ? VB 51 21.5
Tomotherapy ? VB 47 20
FIGO international federation of gynecology and obstetrics staging
system, LVSI lymphovascular space invasion, VB vaginal cuff
brachytherapy, 2D-EBRT two-dimensional external beam radiother-
apy, 3D-EBRT three-dimensional external beam radiotherapy
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TABLE 2 Univariate analysis
Variable n 5-Year
OS (%)
95 %
CI
P value 5-Year
DFS (%)
95 %
CI
P value 5-Year
CSS (%)
95 %
CI
P value 5-Year
LRC (%)
95 %
CI
P value
All patients 237 75 69–81 72 66–78 85 80–89 86 81–91
Age (years)
\69 116 83 75–91 0.0004 82 75–89 0.0004 87 81–93 0.25 88 82–94 0.49
[69 121 68 59–77 0.003a 62 52–71 0.003a 82 75–89 85 78–92
LVSI
Negative 160 82 76–88 0.0004 78 71–85 \0.0001 88 82–93 0.007 90 85–95 0.002
Positive 77 60 46–74 0.003a 54 41–67 0.0008a 77 67–87 0.06a 75 63–87 0.02a
FIGO stage
Ia/b/IIA 75 86 78–94 82 73–91 94 88–99 94 89–99
Ic 75 78 67–89 0.0013 75 67–73 0.001 89 81–97 0.0002 93 87–99 0.0001
IIb 46 61 45–77 0.01a 62 47–77 0.008a 71 57–85 0.002a 74 64–84 0.0008a
III 41 54 37–81 58 41–75 63 45–87 60 50–70
Histology
Endometrioid 181 77 70–84 0.06 75 68–82 0.01 88 83–93 0.003 89 84–94 0.01
Clear cell/papillary 56 69 55–82 61 48–74 0.08a 73 61–85 0.02a 79 67–91 0.08a
Grade
1–2 169 80 73–87 0.0006 79 72–85 0.0002 89 84–94 0.004 89 84–94 0.04
3 68 63 50–76 0.005a 51 37–65 0.002a 73 60–86 0.03a 73 58–88 0.32a
Lymphadenectomy
Not performed 111 69 60–78 0.01 65 57–75 0.03 75 65–82 0.01 76 69–83 0.04
Performed 126 80 72–88 0.08a 78 70–86 0.24a 88 82–94 0.08a 86 80–92 0.32a
Lymph nodes
Positive 28 57 55–59 0.02 58 56–60 0.005 71 53–89 0.01 65 63–67 0.0001
Negative 209 77 71–83 0.16a 74 68–80 0.04a 86 81–91 0.08a 89 84–93 0.0008a
Washing
Negative 222 77 71–83 0.03 74 68–80 0.009 86 81–91 0.05 88 83–93 0.0029
Positive 15 51 48–54 0.24a 45 42–48 0.07a 67 64–70 0.4a 65 62–68 0.02a
LVSI lymphovascular space invasion, OS overall survival, DFS disease-free survival, CSS cancer-specific survival, LRC locoregional control,
CI confidence interval, FIGO international federation of gynecology and obstetrics staging system
a P values after Bonferroni multiple correction analysis
TABLE 3 Multivariate Cox analysis
Variable OS DFS CSS LRC
RR P value RR P value RR P value RR P value
Age [69 years 1.04 0.0006 1.11 0.0003 – NS – NS
Stage
Ia/b/IIa vs. 1.53 0.0001 1.99 0.001 1.03 \0.0001 1.12 0.005
Ic vs. IIb vs. III
LVSI positive 1.72 0.04 1.63 0.01 1.51 0.01 1.02 0.01
Lymphadenectomy (not performed) 1.08 0.02 1.75 0.02 1.13 0.01 1.09 0.01
Grade 3 histology 1.38 0.01 1.35 0.005 1.33 0.04 1.34 0.01
LVSI lymphovascular space invasion, OS overall survival, DFS disease-free survival, CSS cancer-specific survival, LRC locoregional control,
NS nonsignificant, RR relative risk
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bowel obstruction; she developed an acute abdomen
requiring emergency surgery and died 1 week later. We
registered two patients with severe chronic lymphedema,
one of whom had severe intestinal toxicity requiring sur-
gery. One patient had a radiation-induced sacral fracture.
According to the RT technique, the 5-year Kaplan–Meier
estimate of grade 3 or more toxicity was 0 % for VB alone,
6 % (95 % CI, 1–11) for helical Tomotherapy ? VB, 9 %
(95 % CI, 1–17) for 3D-EBRT ? VB, and 22 % (95 % CI,
12–32) for 2D-EBRT ? VB (P = 0.002; Fig. 1).
Second Cancers
In a follow-up period of 10–151 months, 24 patients
(10 %) were diagnosed with second cancers after PORT.
The 5- and 10-year estimated second-cancer incidence was
9 % (95 % CI, 5–13) and 23 % (95 % CI, 13–33),
respectively, for the whole population. The 10-year esti-
mated second-cancer rate was 19 % (95 % CI, 10–29) in
patients younger than 60 years at diagnosis versus 15 %
(95 % CI, 9–21) compared with those 60 years or more
(P = 0.46). In 4 of 24 women, the malignancy was situated
inside or in close proximity to the irradiated volume. The
most common in-field second cancers were bladder (n = 1)
and colorectal (n = 3) cancer. The most common out-of-
field malignancy was breast cancer (n = 12). According to
the RT technique, the 5-year estimated second-cancer
incidence was 0 % for helical Tomotherapy, 5 % for
3D-EBRT (95 % CI, 1–9), 7 % for VB alone (95 % CI,
1–13), and 12 % (95 % CI, 4–20) for 2D-EBRT (P = 0.01).
DISCUSSION
It is recognized that EBRT in patients with EC leads to
better pelvic control compared with surgery alone. A
favorable influence on survival, however, has failed to be
shown in several randomized trials and meta-analyses.3–6,8
Therefore, the life expectancy of these patients should be
taken into consideration to tailor adjuvant RT with the final
aim of keeping good LRC while preventing RT-related side
effects. Depending on the treatment technique, prognostic
factors, and median follow-up time, in early stage disease
LRR rates are in the range of 5–15 %.15,16 Our results
compare well with the literature (14 %; 95 % CI, 9–19)
and confirm good LRC with PORT (Table 4). Patients
treated with VB alone had a 5-year LRC of 89 %. Well-
selected high- to intermediate-risk patients according to the
PORTEC-2 inclusion criteria had an LRC rate of 96 % at
5 years. These results are in line with those obtained in
PORTEC-2, suggesting the feasibility of such an approach
in an appropriately selected subgroup of patients.10 It is
important to note that in the PORTEC-2 study, there was
also a significant quality-of-life advantage for patients
receiving VB alone.17 Serious complications in 3–5 % of
patients after PORT have been reported in various ran-
domized trials and, as in our patients, concerned mainly the
gastrointestinal tract.3,4,6,9 In our study, severe complica-
tions were diagnosed in nearly 10 % of the patients. These
higher-than-expected rates of severe late complications are
in line with what is reported in other studies using
EBRT ? VB.18 We agree that the benefit of VB as a boost
after EBRT is questionable.19 The increased incidence of
injury to the bowel might be explained by the fact that after
hysterectomy, the small-bowel loops occupy the place of
the uterus, thereby receiving high doses of EBRT and
remaining close to the VB source. We have recently
abandoned the systematic use of the VB boost, offering this
additional treatment only to patients with cervical invasion
or positive vaginal margins. In our series, we showed that
the change from 2D- to 3D-EBRT and to helical Tomo-
therapy significantly decreased the incidence of severe side
effects. The use of IMRT for gynecologic cancers is still a
matter of debate. The largest prospective study comparing
non-IMRT versus IMRT showed a reduction in grade 3 or
more long-term toxicity from 17 to 6 %.20 Other retro-
spective series comparing 3D-EBRT versus IMRT after
TAH-BSO have failed to show any benefit.21 A recent
phase II feasibility trial by the radiation therapy oncology
group reported a nonsignificant 12 % reduction in grade 2
or more bowel adverse events in patients treated with
IMRT after TAH-BSO.22 A phase III randomized trial is
warranted to confirm the potential benefits of IMRT in EC.
In our series, the 5-year second-cancer incidence was 0 %
for helical Tomotherapy, 5 % for 3D-EBRT, and 12 % for
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2D-EBRT, keeping in mind the shorter follow-up in
Tomotherapy patients. Onsrud et al.11 analyzed the long-
term outcome of a randomized trial of postoperative
VB ? EBRT versus VB alone. After a median follow-up
of 20.5 years, women younger than 60 years treated with
VB ? EBRT had a significantly higher mortality rate due
to second malignancies (hazard ratio, 2.02; 95 % CI,
1.3–3.1). It should be noted that the RT delivery in that
study was performed mainly with cobalt-60 using a two-
field technique. This technique fully exposes the bladder
and the bowel to high doses of radiation. The 15-year rates
of second cancers in the PORTEC-1 randomized trial were
22 % in patients treated with adjuvant EBRT versus 16 %
in the observational group (P = 0.10). The incidence rates
were compared with those of an age-and sex-matched
population. The observed versus expected ratios were 1.40
for the total group (1.62 for EBRT and 1.2 for the obser-
vational group, P not significant). The predominant cancer
types were gastrointestinal cancer (6.2 % in the EBRT
group vs. 3.2 % in the observational group) and breast
cancer (4.8 % in the EBRT group vs. 6.6 % in the obser-
vational group). These differences did not reach statistical
significance.15 Chaturvedi et al.23 reported on a series of
101,760 cervical cancer patients with more than 40 years
of follow-up who were treated (n = 52,613) or not treated
(n = 27,382) with RT. They observed 12,496 incidents of
second cancers [standard incidence ratio (SIR) = 1.30,
95 % CI, 1.28–1.33]. Compared with the general popula-
tion, the excess absolute risk was 22.7 per 10,000 person-
years. Cervical cancer patients treated with RT as opposed
to those not treated with RT were at increased risk of
second cancers at any site, and the SIR was dependent on
the amount of RT administered. Heavily irradiated organs
located in the irradiated field and receiving[3 Gy (average
radiation dose was 10–66 Gy depending on the location of
the organ) had an SIR of 1.59 (95 % CI, 1.16–1.26),
compared with moderately (1–3 Gy) and lightly (\1 Gy)
irradiated sites (SIR = 1.30, 95 % CI, 1.54–1.66, and
SIR = 1.21, 95 % CI, 1.16–1.26, respectively). This study
demonstrates that the risk of RT-induced second cancers
increases with time and that there is an RT dose effect.
Our study adds information to the ongoing discussion in
prescribing adjuvant EBRT versus VB and the technology
of EBRT. Nevertheless, because of its retrospective
approach, it has several limitations. We could not obtain
information regarding urinary incontinence or fecal leak-
age, which are well-known side effects particularly after
EBRT and are better assessed in quality-of-life studies.
Lymphadenectomy was heterogeneously performed.
Finally, we believe that RT and chemotherapy should be
considered for patients with locally advanced disease and
those with clear-cell or serous-papillary histology on the
basis of the high frequency of distant recurrence and LRR
observed.24–27 The role of chemotherapy in stage I–II
disease with high-risk pathologic features is under evalu-
ation in the ongoing PORTEC-3 trial.
CONCLUSION
For patients with high- or intermediate-risk EC, VB
alone offers high rates of local control with no severe
complications. EBRT should be tailored to patients with
high-risk features because the possible severe late toxicity
may outweigh the benefits. The addition of a VB boost
after EBRT is associated with higher-than-expected late
severe complications. The correlation between severe late
toxicity and RT techniques is observed in our study. When
EBRT is indicated, IMRT and daily image-guided RT
should be considered as a viable treatment option to min-
imize severe late toxicity. Patients should be informed
about the potential increased risk of second malignancies
after the diagnosis of EC and PORT because 2D-EBRT
techniques significantly increase the risk of second tumors
and the severity of side effects. Longer follow-up and more
patients are needed to confirm the lowest second cancer
rates obtained with IMRT in this study. The potential
benefits observed with IMRT should be confirmed in a
randomized trial.
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